Recent

% | $
Quotes you view appear here for quick access.

Enzon Pharmaceuticals Inc. Message Board

bluestarrairlines 279 posts  |  Last Activity: Apr 7, 2015 9:36 AM Member since: Oct 30, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Sage and wise advise

    by bluestarrairlines Apr 7, 2015 9:31 AM
    bluestarrairlines bluestarrairlines Apr 7, 2015 9:36 AM Flag

    who's the idiot who can't spell idiot?

  • bluestarrairlines by bluestarrairlines Apr 7, 2015 9:31 AM Flag

    Take the gains today from ONVO and buy VRNG. VRNG has many more catalysts in the near term. Once you build back your ONVO losses with VRNG then reinvest in ONVO when it's around a buck 4-5 months from now.

  • Reply to

    L'Oreal Paid Partnership + Organovo

    by mistabimsta Apr 7, 2015 8:21 AM
    bluestarrairlines bluestarrairlines Apr 7, 2015 9:14 AM Flag

    Understood Bomba and maybe I appear to cynical but I know from experience that these type of deals are longshots as nothing has been accomplished other than a contract for a development project with some bells and whistles. Immediate revenue from this is less than $200K over the next 2 years in my opinion. More important is the lack of data the company produced at society of toxicology in San Diego 2 weeks ago. The exhibitor hosted session was a disaster as they didn't meet any expectations of data presentation but instead leaded a round-table discussion on the needs for advanced liver models. Basically this screamed that they have nothing ready for prime -time and just a BS marketing exercise. Oh and speaking of marketing you should see the new advertisements they produced for SOT. The most morbid, awful piece of marketing I've ever seen in my 25 years in the life Science industry.

    Sentiment: Strong Sell

  • Reply to

    L'Oreal Paid Partnership + Organovo

    by mistabimsta Apr 7, 2015 8:21 AM
    bluestarrairlines bluestarrairlines Apr 7, 2015 8:50 AM Flag

    Please!... this deal is based on feasibility of an undeveloped model for L'Oreal's needs. Potentially great news but this is a very long-term development project which needs to pass many hurdles before any serious revenue is captured. 2-3 5 years! This retail horde of investors in ONVO is absolutely nuts in my opinion. cool it and take a back seat until they develop models which are non-exclusive and have some real commercial prowess.

    Sentiment: Strong Sell

  • bluestarrairlines bluestarrairlines Mar 20, 2015 10:42 AM Flag

    Are you insane? just because the collaborate loosely and I mean loosely you shouldn't draw assumptions that this was screened on the ONVO platform? before testing biologics on the platform one would start with small molecules... walk before you run ...know what I mean. If they are showing clinical data that means this program is years old having tested it in rodent, dog, Cyno in vivo before sticking it in humans. This was done years ago. Bad pumpers!

  • bluestarrairlines bluestarrairlines Mar 18, 2015 6:05 PM Flag

    Jim McKim has the worst reputation of any toxicologist in the country. Ask any one from Cyprotec. Jim sold his company to Cyprotec and got sued for fraud.

    Sentiment: Strong Sell

  • Reply to

    Insphero

    by jathman Feb 28, 2015 3:34 PM
    bluestarrairlines bluestarrairlines Mar 13, 2015 1:18 PM Flag

    I'm very familiar with the advanced 3D liver models in the marketplace and please know that both Hepregen and InSphero models recapitulate the in vivo liver toxicity not currently seen in 2D assays. Both of the technologies have numerous studies and publications. Next week actually kicks off the Society of Toxicology meeting in San Diego where these two companies will present more data with global collaborations. The cost of these models are a substantial selling point if you consider the screening needs for pharmaceutical safety groups. As a toxicologist I see little evidence from the Onvo model and what has been published to date, that their cost justifies the models ability to better predict... in a screening capacity... human toxicity.

  • Reply to

    Organovo is a Lifescience/Heathscience company

    by lfescience Feb 3, 2015 8:09 AM
    bluestarrairlines bluestarrairlines Feb 3, 2015 9:57 PM Flag

    I get it just fine. This is not a life sciences company... they have no product revenue and won't for many years to come...Instead I classify ONVO as a baseless hype machine selling futures to suckers.

  • Reply to

    How's the top revenue line looking?

    by bluestarrairlines Feb 3, 2015 3:08 PM
    bluestarrairlines bluestarrairlines Feb 3, 2015 3:24 PM Flag

    Wouldn't share accum drive the price higher. The PPS is down 3% today alone.

  • Reply to

    How's the top revenue line looking?

    by bluestarrairlines Feb 3, 2015 3:08 PM
    bluestarrairlines bluestarrairlines Feb 3, 2015 3:13 PM Flag

    OK... thus the drop in the PPS!

  • bluestarrairlines by bluestarrairlines Feb 3, 2015 3:08 PM Flag

    Got Revenue?? Deals/// announcements?? Bueller??...anyone!

  • Reply to

    ampiprobe approval & appeal denial

    by enzolong Jan 10, 2015 11:34 PM
    bluestarrairlines bluestarrairlines Jan 20, 2015 5:30 PM Flag

    ampiprobe is a dog... compared to other rna amplification technologies. I know I've seen the technology.

  • Reply to

    Ouch -what happened to my ONVO??

    by raydonovan1 Jan 17, 2015 10:52 AM
    bluestarrairlines bluestarrairlines Jan 20, 2015 1:17 PM Flag

    INSPHERO happened to ONVO

  • bluestarrairlines bluestarrairlines Dec 19, 2014 10:16 AM Flag

    I wouldn't recommend anyone take anyone's word for it...especially on this msg board. What I would recommend is you take a look at the data which is out there and conduct your own DD. I'd begin with regenemed for one. These websites have plenty of information. My guess is ONVO will likely purchase one of these smaller private companies to fill the gap between their future technology prospects and what the industry can use today.

    Sentiment: Strong Sell

  • bluestarrairlines bluestarrairlines Dec 19, 2014 9:14 AM Flag

    I suggest you take a look at the Hepregen website and see the list of publications which tout the technology and answer the questions ONVO purports to be novel for their model only. Guys this is a joke of a debate, if you only knew. Roche has a charter to evaluate different models and they have. ONVO is just one and the data that came out of the evaluation was incredibly basic. You can see the same data posted from all the advanced liver model providers that have all had similar colloborations. Hepregen for example has BI and Pfizer data sets you can see.

  • bluestarrairlines bluestarrairlines Dec 19, 2014 7:24 AM Flag

    physiologically relevant doses are measured in units called Cmax. look it up, typically IC50's are generated during a dose response experiment, concentrations ranging from low uM to 1 mM. from these you generate an IC50 and compare that number to Cmax (physiologically relevant max dose) and the closer the ratio to "1" the more relevant. All comparative studies have done this to be honest not sure how ONVO could even make this statement. It makes me question this slight, not scientific spin they place on everything. For instance, Astra Zeneca published a poster on just subject recently. A 53 marketed compounds study with known DILI (drug induced liver injury). The non- ONVO model stacked up very well with hepatotoxicants and non-hepatotoxicants at physiological dosses. so this is plainly not true. Please don't quote snippets and miss-report what they mean. This is very unfair for the general public deciding if this investment has merit. It makes me question your motives.

  • Reply to

    BlueStarAirlines

    by lewis_berry_1 Dec 18, 2014 10:27 PM
    bluestarrairlines bluestarrairlines Dec 19, 2014 7:13 AM Flag

    Sorry but you are so wrong with your perception of what restrictions are at my place of employment. We have cell phones, iPads and even laptops. ....all with internet access. Some of us even have a sense of humor, mine happens to surround vintage 80's movies...thus Bluestar. I thought it was rather suiting and funny. Love gecko. never saw the remake though. Biotech lab personnel aren't restricted from internet access... come on....

    Sentiment: Strong Sell

  • Reply to

    InSphero AG

    by bluestarrairlines Dec 18, 2014 10:28 AM
    bluestarrairlines bluestarrairlines Dec 18, 2014 3:43 PM Flag

    ONVO is keeping any characterization work very secret. So you are correct. But why wouldn't they release the details of how they can de-risk the drug development process better than the models which already are on the market and have 3 years of data behind them?

  • Reply to

    InSphero AG

    by bluestarrairlines Dec 18, 2014 10:28 AM
    bluestarrairlines bluestarrairlines Dec 18, 2014 3:31 PM Flag

    sorry I have to reply. Management team is great and the company has recruited heavy hitters...no doubt about that. I used to work for Greg at Applied bio systems. before we were acquired by life technologies. He's the best of the best. What I'm tring to convey to this board is that from a industry customer prespective we have not seen compelling evidence of superiority of the ONVO model. BTW ONVO does not sell assays they sell a liver model which one runs assays. Promega and life technologies sell assays.

  • Reply to

    InSphero AG

    by bluestarrairlines Dec 18, 2014 10:28 AM
    bluestarrairlines bluestarrairlines Dec 18, 2014 3:17 PM Flag

    She is a regenerative medicine scientist and not a toxicologist. completely different world. She probably understand liver biology but not necessarily the applications or the business aspect of these labs.

ENZN
0.410.00(-0.12%)Jun 29 3:58 PMEDT